Company

Suzhou Infinory Pharmaceuticals, LLC

Suzhou Infinory develops oncolytic virus drugs and related technologies.

About

Founded in 2020 and based in Suzhou, China, Suzhou Infinory Pharmaceuticals develops oncolytic virus drugs, including YH01 for triple-negative breast cancer. Its OCDP™ platform has developed more than ten oncolytic viruses. In March 2024, the company closed Series A1 funding from Sunbow Capital to support a Phase I study of YH01.

4Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in